FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy
FDA clearance expands development of forazapadin into a second degenerative muscle disease with significant unmet medical needFSHD Canada Foundation to provide up to US$5 million in non-dilutive financing toward the
Satellos got permission to test a new medicine for muscle disease. This shows the company is moving forward with a treatment people need.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.